TAK1 has been shown to decrease in high-grade human prostate cancer, and TAK1 deficiency promotes prostate tumorigenesis by increasing androgen receptor (AR) protein levels and activity or by activating the p38 MAPK pathway (Huang et al., 2021; Wu et al., 2012). Here, MAP3K7 is linked to prostate carcinoma.